[{"id":"22aafbd8-3de1-4972-a79b-76ff923785ec","acronym":"ELIPSE","url":"https://clinicaltrials.gov/study/NCT04797728","created_at":"2021-03-15T15:53:41.485Z","updated_at":"2024-07-02T16:36:01.820Z","phase":"Phase 1","brief_title":"Elacestrant in Preoperative Setting, a Window of Opportunity Study","source_id_and_acronym":"NCT04797728 - ELIPSE","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PTTG1 • RRM2 • CDC20 • CEP55 • UBE2C","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PTTG1 • RRM2 • CDC20 • CEP55 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 02/09/2021","start_date":" 02/09/2021","primary_txt":" Primary completion: 02/08/2022","primary_completion_date":" 02/08/2022","study_txt":" Completion: 02/25/2022","study_completion_date":" 02/25/2022","last_update_posted":"2022-10-26"},{"id":"5edcf750-2efe-4fff-8613-fe4db76a5f90","acronym":"","url":"https://clinicaltrials.gov/study/NCT02770391","created_at":"2021-01-20T21:52:08.137Z","updated_at":"2024-07-02T16:36:08.521Z","phase":"Phase 2","brief_title":"Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer","source_id_and_acronym":"NCT02770391","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" TMPRSS2 • HSD3B1 • FKBP5 • UBE2C","pipe":"","alterations":" ","tags":["TMPRSS2 • HSD3B1 • FKBP5 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 04/29/2020","primary_completion_date":" 04/29/2020","study_txt":" Completion: 04/29/2020","study_completion_date":" 04/29/2020","last_update_posted":"2022-06-21"},{"id":"c3fca746-2c87-4c39-b71e-3fcf60265718","acronym":"PHOENIX","url":"https://clinicaltrials.gov/study/NCT03740893","created_at":"2021-01-18T18:19:29.637Z","updated_at":"2025-02-25T15:08:06.285Z","phase":"Phase 2","brief_title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer","source_id_and_acronym":"NCT03740893 - PHOENIX","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • CD8 • IFNG • LAG3 • BIRC5 • CXCL9 • PARP1 • TYMS • PTTG1 • RRM2 • CDC20 • CCNB1 • CEP55 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2020-02-21"},{"id":"91f25517-3648-4010-96ee-c139f5875d49","acronym":"CABA-BONE","url":"https://clinicaltrials.gov/study/NCT02512458","created_at":"2021-01-18T12:08:14.634Z","updated_at":"2024-07-02T16:36:50.251Z","phase":"Phase 2","brief_title":"Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer","source_id_and_acronym":"NCT02512458 - CABA-BONE","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" TP53 • AR • CYP17A1 • NKX3-1 • UBE2C","pipe":" | ","alterations":" AR expression • TP53 expression","tags":["TP53 • AR • CYP17A1 • NKX3-1 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/29/2015","start_date":" 10/29/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/27/2019","study_completion_date":" 12/27/2019","last_update_posted":"2020-02-10"}]